Sosei | News

September 2010	Sosei Announces Issuance of Stock Options (Stock Acquisition Rights)
August 2010	Sosei Acquires Activus Pharma
August 2010	Summary of Consolidated Financial Results for the 1Q ended 30 June 2010 (abridged English version)
June 2010	Sosei to Acquire Activus Pharma
May 2010	Sosei Announces Stock Option (Stock Acquisition Rights) Allotment Sosei Announces a New Appointment to its Board of Directors
May 2010	Summary of Consolidated Financial Results for the Financial Year ended 31 March 2010 (abridged English version)
May 2010	Sosei Announce Start of Phase III Clinical Study with QVA149
February 2010	Summary of Consolidated Financial Results for the 3Q ended 31 December 2009 (abridged English version)
January 2010	Update on Phase I Clinical Study of RS(+) Mefloquine for Malaria

November 2009	Summary of Consolidated Financial Results for the First Half Year ended 30th September 2009 (abridged English version)
November 2009	Sosei Signs Definitive Distribution Agreement with ASKA for Commercialisation of SOH-075 (NorLevo®)
October 2009	Update on NVA237 and QVA149 for Chronic Obstructive Pulmonary Disease
October 2009	Sosei Announces Deal with UK Biotech Company
October 2009	Sosei Assigns AD 923 Assets to Pharmasol
September 2009	Sosei Announces Filing of NDA for SOH-075 (NorLevo®) in Japan
September 2009	QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting
August 2009	Summary of Consolidated Financial Results for the 1Q ended 30th June 2009 (abridged English version)
July 2009	Sosei Announces Enrolment of First Patient in Phase III Clinical Study with NVA237
June 2009	Sosei and Vectura Announce Start of Phase III Clinical Study with NVA237
May 2009	NVA237 Manufacturing Process Related Patent Granted in Europe (Summary of Japanese PR)
May 2009	Summary of Consolidated Financial Resultsfor the Financial Year ended 31st March 2009(abridged English version)
March 2009	SD118 Patent Granted in Europe (Summary of Japanese PR)
March 2009	Sosei Sells Chronotherapeutics Patents (Summary of Japanese PR)
February 2009	Announcement of New Appointments
February 2009	Summary of Consolidated Financial Resultsfor the 3Q ended 31st December 2008 (Abridged English version)

December 2008	Sosei Announces Buyback of the Commercialization Rightsto AD 923 from Mundipharma Revision Announcement of Financial Forecasts for FY2008
December 2008	Sosei Confirms the Safety of SD118 in Two Phase I Trials
November 2008	Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for theTreatment and Prophylaxis of Malaria
November 2008	Neurosolutions and Sosei Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting
November 2008	Summary of Consolidated Financial Resultsfor the First Half Year ended 30th September 2008(abridged English version)
October 2008	Sosei Agrees Terms with ASKA for Commercialisation ofSOH-075 (NorLevo®)
October 2008	NVA237 Phase II results presented at the European Respiratory Society Annual Meeting show promising efficacy and tolerability with potentially fasteronset than tiotropium.
August 2008	Summary of Consolidated Financial Resultsfor the 1Q ended 30th June 2008 (abridged English version)
July 2008	Sosei Announces Completion of Phase III Trial for NorLevo®
May 2008	Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2008(abridged English version) Sosei Announces Outcome of Strategy Review
March 2008	Sosei Announces Temporary Halt toAD 923 CBP Phase III Studies in Europe
February 2008	Sosei Announces Initiation of Phase III Trial for NorLevo®
February 2008	Summary of Consolidated Financial Resultsfor the 3Q ended 31st December 2007(abridged English version)
February 2008	Sosei Announces Start of AD 923 Phase III Studies in Europe
January 2008	Update of NVA237 and QVA149 Development Programme

December 2007	Sosei and Vectura Announce Start of Phase II Efficacy Study of QVA149
December 2007	Sosei Announces New Fundraising
November 2007	Sosei Announces Approval to Start AD 923 Phase III Studies in Europe
November 2007	Sosei Announces Update on Phase I Trials for SD118
November 2007	Sosei and Vectura Announce Start of Phase II Studies of QVA149 for the Treatment of COPD
November 2007	Summary of Consolidated Financial Resultsfor the First Half Year ended 30th September 2007(abridged English version )
September 2007	Sosei Announces Completion of Phase II Trialof AD 337 in Fibromyalgia Syndrome
August 2007	Sosei Announces Completion of Phase I Trial for NorLevo®
August 2007	Summary of Consolidated Financial Resultsfor the First Quarter ended 30th June 2007(abridged English version)
August 2007	Sosei and Vectura Announce Start of Phase II Clinical Studywith NVA237 in the USA
July 2007	Vectura and Sosei Announce NVA237 Dose Ranging Study inNew Device
May 2007	Sosei Announces Start of SD118 Phase I Studies
May 2007	Sosei Announces New Appointments to its Board of Directors
May 2007	Sosei Announces Successful Completion of AD 923Pharmacokinetic Study in the USA
May 2007	Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2007
March 2007	Sosei Announces Completion of Exercise of Stock Acquisition Rights
March 2007	Sosei Announces Significant Exercise of Stock Acquisition Rights
March 2007	Sosei Announces Significant Exercise of Stock Acquisition Rights
March 2007	AD 923 Commences Phase I Clinical Development in the USA
March 2007	Sosei Announces Significant Exercise of Stock Acquisition Rights
February 2007	Sosei Announces Progression of SD118 Towards Phase I Studies
February 2007	Summary of Consolidated Financial Resultsfor the 3Q Ended 31st December 2006(abridged English version)
January 2007	Sosei Announces Significant Exercise of Stock Acquisition Rights
January 2007	Sosei Announces New Fundraising

November 2006	Sosei Announces that QVA149 Clinical Development starts in2007 and Updates the Status of NVA237
November 2006	Sosei Announces Results of AD 452 Phase IIb Clinical Trial
November 2006	Sosei Announces Initiation of Phase I Trial for NorLevo®
November 2006	Announcement of New Appointments Summary of Consolidated Financial Resultsfor the First Half Ended 30th September 2006( abridged English version )
November 2006	Revision Announcement of Financial Forecasts for FY2006
October 2006	Sosei Announces Start of Phase II Trial of AD 337 in Fibromyalgia Syndrome
August 2006	Summary of Consolidated Financial Resultsfor the First Quarter ended 30th June 2006( abridged English version )
June 2006	Sosei and Vectura Announce Successful Completion of Phase IIb Trial of NVA237 for COPD
June 2006	Sosei Announces Agreement with Mundipharma for AD 923 Revision Announcement of Financial Forecast for FY2006
June 2006	Sosei Business Strategy Update and Portfolio Review
May 2006	Sosei Discontinues Development of SOU-001 Sosei Announces Reorganization of its Corporate Structure under Holding Company Sosei Announces Company Name Change of two Affiliates Consolidated Financial Results for the Fiscal Year Ended March 31, 2006
May 2006	Revision Announcement of Financial Forecasts for FY2005
March 2006	Announcement of New Appointments Sosei sells off its subsidiary, SC Consulting
February 2006	Amendment of Consolidated Financial Resultsfor 9 Months Ended 31 Dec. 2005
January 2006	Sosei updates the status of Eligard

December 2005	Sosei Sub-licenses NorLevo to Hexal for Australia
December 2005	Sosei Business Update and Revised Financial Forecast Following Acquisition of Arakis
November 2005	Revision Announcement of Financial Forecast for FY2005
November 2005	Arakis Completes Phase I Trials of AD 337 in Fibromyalgia Syndrome
October 2005	Arakis and Vectura Announce Start of Phase IIb Trial of NVA237 for COPD
October 2005	H.G.F. License Contract
September 2005	Arakis Commences Phase IIB Trial for Rheumatoid Arthritis Drug
July 2005	Sosei to Acquire Arakis for £106.5 million
June 2005	NeuroSolutions' Collaboration with Sosei's Drug ReprofilingPlatform® Yields Possible New Treatment for Neuropathic Pain
June 2005	Sosei's SOU-001 Project Moves to Phase II Clinical Study
May 2005	Sosei Adopts "Company with Committees" System
March 2005	Sosei Appoints David Chiswell as Non-Executive Chairman
March 2005	Itochu and Sosei Agree on Capital and Business Alliances
February 2005	Sosei Files Marketing Authorisation Application for SOT-375
February 2005	Sosei in-license urology drug from Otsuka
February 2005	SOT-107 Granted Orphan Designation in Japan
February 2005	EPS and Sosei establish a biopharmaceutical JV in China
January 2005	Lead antibodies identified under SOA-002 project collaboration

November 2004	Sosei announces the launch of its US company and deal with Mitsubishi Pharma
October 2004	Announcement on Revision of Financial Forecast for FY2004
September 2004	Announcement of New Appointments
July 2004	Announcement of Movement in Major Shareholders
June 2004	Announcement of Earnings Forecast for FY2004
June 2004	Sosei Initiates Phase I Clinical Trial of Oral SOU-001